US-based medical device technology company Xenter has introduced its investigational dual sensor guidewire for transcatheter aortic valve replacement (TAVR) procedures.
Unveiled at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference in San Francisco, California, the first-of-its-kind wireless guidewire is intended for collection of an extensive range of key real-time data points.
These points, according to Xenter, serve as an aortic regurgitation measurement (xAR) and clinical decision support tool for considerably improving the prediction of para valvular leak (PVL) during the TAVR procedure.
The capability of the guidewire is designed to assist in the collecting and processing of large amounts of data as well as for facilitating the data required for artificial intelligence (AI) decision-making systems.
Xenter chairman and CEO Rich Linder said: “We built Xenter to enable Artificial Intelligence (AI) tools to be utilised with ease and accuracy using new smart/wireless medical devices that transmit real-time Physical Intelligence (PI) data.
“Xenter is pioneering smart medical devices and a wireless ecosystem that eliminate the capital equipment and mobile carts that clutter hospitals throughout the world.”
Linder further stated that Xenter is introducing the XMD cloud, which integrates with hospital electronic health records (EHRs) and facilitates AI-driven clinical decision support tools based on real-time PI data.
According to Xenter, the goal of the guidewire is to help make more informed clinical decisions and enhance patient outcomes.
In addition, the guidewire is designed to seamlessly operate within a proprietary wireless ecosystem in the cardiac catheterisation lab, thereby enhancing accessibility to real-time data and analysis.
Mainline Healthcare in Philadelphia cardiovascular medicine system chief William Gray said: “TAVR SmartWire will enable the real-time measurement of aortic and left ventricular pressure information in a single workhorse device that can be used to develop a measurement of Aortic Regurgitation (AR).
“We plan to clinically evaluate TAVR SmartWire and provide physicians with a real-time AR measurement called xAR.”
